NO933000L - Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer - Google Patents

Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer

Info

Publication number
NO933000L
NO933000L NO933000A NO933000A NO933000L NO 933000 L NO933000 L NO 933000L NO 933000 A NO933000 A NO 933000A NO 933000 A NO933000 A NO 933000A NO 933000 L NO933000 L NO 933000L
Authority
NO
Norway
Prior art keywords
inactivator
prophylaxis
drug
manufacture
treatment
Prior art date
Application number
NO933000A
Other languages
English (en)
Norwegian (no)
Other versions
NO933000D0 (no
Inventor
Bernd Eisele
Ulrich Delvos
Andreas Jessel
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of NO933000D0 publication Critical patent/NO933000D0/no
Publication of NO933000L publication Critical patent/NO933000L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO933000A 1992-08-24 1993-08-23 Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer NO933000L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4227762A DE4227762A1 (de) 1992-08-24 1992-08-24 Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten

Publications (2)

Publication Number Publication Date
NO933000D0 NO933000D0 (no) 1993-08-23
NO933000L true NO933000L (no) 1994-02-25

Family

ID=6466096

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933000A NO933000L (no) 1992-08-24 1993-08-23 Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer

Country Status (9)

Country Link
US (1) US5939389A (fr)
EP (1) EP0586909A3 (fr)
JP (1) JPH06157343A (fr)
KR (1) KR100290753B1 (fr)
AU (1) AU671287B2 (fr)
CA (1) CA2104636C (fr)
DE (2) DE4227762A1 (fr)
IL (1) IL106776A0 (fr)
NO (1) NO933000L (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
WO1997022347A1 (fr) * 1995-12-18 1997-06-26 Stichting Sanquin Bloedvoorziening Potentialisation des proprietes d'inhibition du complement et de la coagulation d'un inhibiteur de c1
DE19827750C1 (de) 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
US20040152635A1 (en) * 1998-06-22 2004-08-05 Albrecht Groner Modified C1 esterase inhibitor for blocking the infectiousness of HIV
AU2006203549B2 (en) * 2000-01-31 2008-10-09 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
EP1252184B1 (fr) * 2000-01-31 2008-01-02 Pharming Intellectual Property B.V. Inhibiteur de c1 human produit dans du lait de mammiferes transgeniques
PL1626736T3 (pl) 2003-05-16 2021-05-04 Pharming Intellectual Property B.V. Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego
CA3154415A1 (fr) 2006-10-10 2008-04-17 Regenesance B.V. Oligonucleotide antisens destine a l'utilisation dans la facilitation de la regeneration axonale
DK2758076T3 (en) 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
WO2013093027A1 (fr) 2011-12-22 2013-06-27 Csl Behring Gmbh Utilisation d'un c1-inhibiteur destiné au traitement d'un œdème secondaire du système nerveux central
US10441631B2 (en) 2013-02-28 2019-10-15 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
AU2014224599B2 (en) 2013-03-08 2018-11-08 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
JP2017501968A (ja) 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
EP3302529A4 (fr) 2015-06-03 2019-02-06 The Children's Hospital Medical Center Compositions et procédés pour le traitement de l'atrésie des voies biliaires néonatale
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
WO2018037046A1 (fr) 2016-08-23 2018-03-01 Csl Behring Gmbh Procédé de prévention d'attaques aiguës d'œdème de quincke héréditaire associées à une déficience en inhibiteur de c1 estérase
EP3681517B1 (fr) 2017-09-15 2024-05-08 Cedars-Sinai Medical Center Inhibiteurs de la c1 estérase pour leur utilisation pour améliorer la fonction des organes chez les patients greffés d'organes
EP4247416A1 (fr) 2020-11-20 2023-09-27 CSL Behring GmbH Méthodes de traitement d?un rejet à médiation par anticorps

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
US5271931A (en) * 1988-09-14 1993-12-21 The Scripps Research Institute Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6
US5030578A (en) * 1989-07-10 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Process for the purification of C1-inhibitor
EP0512090B2 (fr) * 1990-10-16 2006-11-22 Sonoran Desert Chemicals LLC Traitement d'inflammations
WO1992022320A1 (fr) * 1991-06-14 1992-12-23 Genentech, Inc. Variantes de l'inhibiteur c1 et traitement des reactions inflammatoires avec l'inhibiteur c1
DE4227735C2 (de) * 1992-08-21 1995-10-12 Leybold Ag Anordnung zum berührungslosen Messen der Dicke von Schichten
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten

Also Published As

Publication number Publication date
AU4477893A (en) 1994-03-03
CA2104636C (fr) 2003-11-11
US5939389A (en) 1999-08-17
JPH06157343A (ja) 1994-06-03
DE4227762A1 (de) 1994-03-03
AU671287B2 (en) 1996-08-22
DE4244735A1 (de) 1994-03-31
EP0586909A3 (fr) 1995-04-05
CA2104636A1 (fr) 1994-02-25
IL106776A0 (en) 1993-12-08
KR100290753B1 (ko) 2001-09-17
EP0586909A2 (fr) 1994-03-16
KR940003564A (ko) 1994-03-12
NO933000D0 (no) 1993-08-23

Similar Documents

Publication Publication Date Title
NO933000L (no) Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer
SE8406538D0 (sv) Novel derivatives of purine
LU90192I2 (fr) Desirudine et ses sels et dérivés pharmaceutiquement acceptables (revasc)
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
ES2036199T3 (es) Procedimiento de obtencion de un preparado farmaceutico administrable a traves de una membrana corporal.
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
LU92425I2 (fr) Dichlorure de radium Ra 2232 et ses dérivés pharmaceutiquement acceptables (XOFIGO®)
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
ATE87214T1 (de) Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc).
ES8609325A1 (es) Un procedimiento para preparar derivados de guanina
DE69905368D1 (en) Oxydiertes thymosin beta 4
SE8000435L (sv) N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
DE3372712D1 (en) A tube set intended for extracorporeal treatment of blood and similar perishable liquids
ES549776A0 (es) Procedimiento para la preparacion de pirrolo-bencimidazoles
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
Schlossberg Multiple erythematous nodules as a manifestation of Pseudomonas aeruginosa septicemia
FI863565A0 (fi) Foerfarande foer framstaellning av nya pyrrobenzimidazoler, pyrrolbenzoxazoler och pyrrolbenztiazoler.
MC1930A1 (fr) Produit antiviral
MY124071A (en) Treatment of viral disease in swine
GR3006147T3 (fr)
DK162477C (da) Anvendelse af gonadoliberin eller den gonadoliberin-analoge buserelin til fremstilling af et farmaceutisk praeparat til behandling af klimakterielle besvaerligheder og patologiske tilstande med forhoejet parathormonspejl
EP0231425A3 (en) Use of a solution of alpha-chymotrypsin
JO1493B1 (en) Pharmaceutical combination for treating high blood pressure

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application